2026-525179-26-00招募中1 期
A study to see how safe a new medicine (NNC6022-0004) is in healthy people and people living with obesity
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 128
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Novo Nordisk A/S
Scientific
Novo Nordisk A/S
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A research study of a new medicine (NNC0650-0013) in healthy men2023-506134-79-00Novo Nordisk A/S60
招募中
1 期
A Phase 1b study to evaluate the safety, pharmacokinetics, and anti-tumour activity of the Myc inhibitor OMO-103 administered intravenously in combination with different drugs in patients with advanced solid tumours2023-504376-21-00Peptomyc S.L.30
已完成
1 期
A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or ObesityObesityNCT07400679Pfizer48
招募中
1 期
A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours2023-504897-39-00Deuteroncology, Deuteroncology60
已完成
1 期
Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia2023-508819-23-00Hutchmed Ltd.22